Celldex Therapeutics CLDX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's investing cash flow?
- Celldex Therapeutics (CLDX) reported investing cash flow of $72.12M in Q1 2026.
- How has Celldex Therapeutics's investing cash flow changed year-over-year?
- Celldex Therapeutics's investing cash flow increased by 67.9% year-over-year, from $42.95M to $72.12M.
- What is the long-term trend for Celldex Therapeutics's investing cash flow?
- Over 3 years (2021 to 2025), Celldex Therapeutics's investing cash flow has grown at a -1.1% compound annual growth rate (CAGR), from -$216.16M to $209.07M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.